Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance

– Strong execution delivered second quarter 2023 total revenues of $957 million – – Commercial excellence drove continued adoption of low-sodium Xywav®; net...

Related Keywords

Russia ,Ukraine ,Japan ,Ireland ,Dublin ,United States ,American ,Andrean Flynn ,Oxybate Xywav ,Rob Iannone ,Epidiolex Epidyolex ,Kristin Bhavnani ,Bruce Cozadd ,Sunosi To Axsome Therapeutics Inc ,Roche Ltd ,European Medicines Agency ,American Academy Of Neurology Annual Meeting ,Jazz Investments ,Exchange Commission ,Jazz Pharmaceuticals ,Share Repurchase Program ,Company Annual Report On Form ,Prnewswire Jazz Pharmaceuticals ,Committee For Medicinal Products Human Use ,Nasdaq ,Head Of Global Corporate Communications ,Hikma Pharmaceuticals ,European Commission ,Gw Pharmaceuticals ,American Academy ,Neurology Annual Meeting ,Orphan Drug Exclusivity ,Idiopathic Hypersomnia ,Medicinal Products ,Human Use ,Statistical Manual ,Mental Disorders ,Fifth Edition ,Fast Track Designation ,Investigational New Drug ,Previously Announced ,Share Repurchase ,Settlement Method ,Exchangeable Senior Notes ,Investmentsi Limited ,Effective Tax ,Dial In Number ,Jazz Pharmaceutical ,Jazz Pharmaceutical Securities ,Annual Report ,Quarterly Reports ,Certain Line Items ,Exchangeable Senior ,Axsome Therapeutics ,Global Corporate ,Jazz Pharmaceuticals Plc ,Pharmaceuticals ,Medical Pharmaceuticals ,Health Care Amp Hospitals ,Earnings ,